Results 271 to 280 of about 355,709 (346)

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET‐Altered Metastatic Thyroid Cancer or Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Selpercatinib is a first‐in‐class, highly selective, RET kinase inhibitor with CNS activity, approved for the treatment of RET‐altered lung, thyroid, and other cancers. We report pharmacokinetic analyses to identify factors affecting selpercatinib steady‐state exposure and support posology in pediatric patients.
Dan Liu, Jan‐Stefan van der Walt
wiley   +1 more source

Twenty-five years of treating advanced NSCLC: what have we achieved?

, 2004
Giuseppe Giaccone
openalex   +1 more source

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients. [PDF]

Thorac Cancer
Kim MJ, Kwak HS, Koh EN, Park CK, Kim YC, Oh IJ, Kim SJ, Lim JH, Ryu JS, Choi CM.   +9 more
europepmc   +1 more source

A Bayesian Approach to Compare Accumulating Survival Data From Clinical Practice With RCT Data: A Case Study in Non‐Small Cell Lung Cancer Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Survival outcomes observed in randomized controlled trials (RCTs) may not always be generalizable to clinical practice. Evaluating whether treatment outcomes in clinical practice are similar to those in RCTs shortly after a new medicine is introduced is important for making informed decisions.
Marjon V. Verschueren, Daniel V. Verschueren, Ewoudt M. W. van de Garde, Lourens T. Bloem   +3 more
wiley   +1 more source

Driver gene-specific prevalence and incidence of brain metastases in non-small cell lung cancer: a meta-analysis encompassing all disease stages. [PDF]

Discov Oncol
Zhang Y, Wen Y, Fan P, Li F, Li M, Wang Z, Wang X, Mao Z, Li Y, Yao Y, Bian L.   +10 more
europepmc   +1 more source

A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Early assessment of efficacy and dose optimization remain critical challenges in the development of anticancer therapies. Empirical models of solid tumor size dynamics—a key prognostic biomarker—have played a central role in addressing these challenges.
Anna Mishina, Kirill Zhudenkov, Gabriel Helmlinger, Kirill Peskov   +3 more
wiley   +1 more source

Emerging Targets in Non-Small Cell Lung Cancer. [PDF]

Lung Cancer (Auckl)
Wang J, Biglow L, Baumgart M.
europepmc   +1 more source

Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1‐Positive NSCLC or NTRK‐Positive Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT To support the benefit–risk assessment and dose justification of repotrectinib for patients with c‐ros oncogene 1 (ROS1) positive non‐small cell lung cancer (NSCLC) or neurotrophin receptor tyrosine kinase (NTRK)‐positive solid tumors, exposure–response analyses were conducted.
Shengnan Du, Zheyi Hu, Jun Shen, Li Zhu, Amit Roy, Justine Lam, Ming Lu, Anna Kondic, Lora Hamuro   +8 more
wiley   +1 more source

Combined Detection of Tumor Stem Cell Markers CD133 and OCT4 in Early Non-Small Cell Lung Cancer Screening and Prognostic Evaluation. [PDF]

Cancer Manag Res
Guan S, Huangfu J, Zhu X, Ge Y, Ding Y, Chen T, Zhang Y, Yang T, Liu H, Zhang L, Chen X, Zhou J.   +11 more
europepmc   +1 more source

A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pembrolizumab is an immune checkpoint inhibitor that has been approved for more than 20 different indications and has shown great survival benefits in various types of cancer. However, the reported benefits of pembrolizumab in patients' quality of life (QoL) have been inconsistent across different studies and different types of cancer.
Yiqin Zou, Yimeng Sun, Sudhamshu Ravva, Lynne I. Wagner, Jiawei Zhou   +4 more
wiley   +1 more source